Brian Bartholmai

Dr. Brian Bartholmai

Mayo Clinic College of Medicine, Rochester, Minnesota, USA
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Chest
Verified
Journal Article
Closed access
EPEvans R Fernández Peréz
Evans R Fernández Peréz
CDCraig E. Daniels
Craig E. Daniels
JSJennifer St. Sauver
Jennifer St. Sauver
THThomas E. Hartman
Thomas E. Hartman
BBBrian Bartholmai
Brian Bartholmai
DSDarrell R. Schroeder
Darrell R. Schroeder

1 September 2015 in Academic Radiology
Verified
Journal Article
Closed access
RMRobert J. McDonald
Robert J. McDonald
KSKara M. Schwartz
Kara M. Schwartz
LELaurence J. Eckel
Laurence J. Eckel
FDFelix E. Diehn
Felix E. Diehn
CHChristopher H. Hunt
Christopher H. Hunt
DKDavid F. Kallmes
David F. Kallmes

5 April 2013 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
FMFabien Maldonado
Fabien Maldonado
TMTeng Moua
Teng Moua
SRSrinivasan Rajagopalan
Srinivasan Rajagopalan
RKRonald A. Karwoski
Ronald A. Karwoski
SRSushravya Raghunath
Sushravya Raghunath
JRJay Ryu
Jay Ryu
Accurate assessment of prognosis in idiopathic pulmonary fibrosis remains elusive due to significant individual radiological and physiological variability. We hypothesised that short-term radiological changes may be predictive of survival.We explored the use of CALIPER (Computer-Aided Lung Informatics for Pathology Evaluation and Rating), a novel software tool developed by the Biomedical Imaging Resource Laboratory at the Mayo Clinic Rochester (Rochester, MN, USA) for the analysis and quantification of parenchymal lung abnormalities on high-resolution computed tomography. We assessed baseline and follow-up (time-points 1 and 2, respectively) high-resolution computed tomography scans in 55 selected idiopathic pulmonary fibrosis patients and correlated CALIPER-quantified measurements with expert radiologists’ assessments and clinical outcomes.Findings of interval change (mean 289 days) in volume of reticular densities (hazard ratio 1.91, p=0.006), total volume of interstitial abnormalities (hazard ratio 1.70, p=0.003) and per cent total interstitial abnormalities (hazard ratio 1.52, p=0.017) as quantified by CALIPER were predictive of survival after a median follow-up of 2.4 years. Radiologist interpretation of short-term global interstitial lung disease progression, but not specific radiological features, was also predictive of mortality.These data demonstrate the feasibility of quantifying interval short-term changes on high-resolution computed tomography and their possible use as independent predictors of survival in idiopathic pulmonary fibrosis.

1 September 2016 in Journal of Thoracic Imaging
Verified
Journal Article
Closed access
JJJoseph Jacob
Joseph Jacob
BBBrian Bartholmai
Brian Bartholmai
SRSrinivasan Rajagopalan
Srinivasan Rajagopalan
MKMaria Kokosi
Maria Kokosi
ANArjun Nair
Arjun Nair
DHDavid M. Hansell
David M. Hansell
Purpose: The aim of the study was to determine whether a novel computed tomography (CT) postprocessing software technique (CALIPER) is superior to visual CT scoring as judged by functional correlations in idiopathic pulmonary fibrosis (IPF). Materials and Methods: A total of 283 consecutive patients with IPF had CT parenchymal patterns evaluated quantitatively with CALIPER and by visual scoring. These 2 techniques were evaluated against: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLco), carbon monoxide transfer coefficient (Kco), and a composite physiological index (CPI), with regard to extent of interstitial lung disease (ILD), extent of emphysema, and pulmonary vascular abnormalities. Results: CALIPER-derived estimates of ILD extent demonstrated stronger univariate correlations than visual scores for most pulmonary function tests (PFTs): (FEV1: CALIPER R 2=0.29, visual R 2=0.18; FVC: CALIPER R 2=0.41, visual R 2=0.27; DLco: CALIPER R 2=0.31, visual R 2=0.35; CPI: CALIPER R 2=0.48, visual R 2=0.44). Correlations between CT measures of emphysema extent and PFTs were weak and did not differ significantly between CALIPER and visual scoring. Intriguingly, the pulmonary vessel volume provided similar correlations to total ILD extent scored by CALIPER for FVC, DLco, and CPI (FVC: R 2=0.45; DLco: R 2=0.34; CPI: R 2=0.53). Conclusions: CALIPER was superior to visual scoring as validated by functional correlations with PFTs. The pulmonary vessel volume, a novel CALIPER CT parameter with no visual scoring equivalent, has the potential to be a CT feature in the assessment of patients with IPF and requires further exploration.

12 November 2021 in Science Immunology
Verified
Journal Article
Open access
ICI. S. Cheon
I. S. Cheon
CLC. Li
C. Li
YSYoung Min Son
Young Min Son
NGN. P. Goplen
N. P. Goplen
YWY. Wu
Y. Wu
JSJie Sun
Jie Sun
Respiratory tissue resident–like CD8 + T cells are associated with chronic lung sequelae post-acute COVID-19.

1 September 2013 in Journal of Thoracic Imaging
Verified
Journal Article
Closed access
BBBrian Bartholmai
Brian Bartholmai
SRSushravya Raghunath
Sushravya Raghunath
RKRonald A. Ba Karwoski
Ronald A. Ba Karwoski
TMTeng Moua
Teng Moua
SRSrinivasan Rajagopalan
Srinivasan Rajagopalan
RRRichard A. Robb
Richard A. Robb
Purpose: High-resolution chest computed tomography (HRCT) is essential in the characterization of interstitial lung disease. The HRCT features of some diseases can be diagnostic. Longitudinal monitoring with HRCT can assess progression of interstitial lung disease; however, subtle changes in the volume and character of abnormalities can be difficult to assess. Accuracy of diagnosis can be dependent on expertise and experience of the radiologist, pathologist, or clinician. Quantitative analysis of thoracic HRCT has the potential to determine the extent of disease reproducibly, classify the types of abnormalities, and automate the diagnostic process. Materials and Methods: Novel software that utilizes histogram signatures to characterize pulmonary parenchyma was used to analyze chest HRCT data, including retrospective processing of clinical CT scans and research data from the Lung Tissue Research Consortium. Additional information including physiological, pathologic, and semiquantitative radiologist assessment was available to allow comparison of quantitative results, with visual estimates of the disease, physiological parameters, and measures of disease outcome. Results: Quantitative analysis results were provided in regional volumetric quantities for statistical analysis and a graphical representation. These results suggest that quantitative HRCT analysis can serve as a biomarker with physiological, pathologic, and prognostic significance. Conclusions: It is likely that quantitative analysis of HRCT can be used in clinical practice as a means to aid in identifying a probable diagnosis, stratifying prognosis in early disease, and consistently determining progression of the disease or response to therapy. Further optimization of quantitative techniques and longitudinal analysis of well-characterized subjects would be helpful in validating these methods.